Alpha 2.0
Login Register
» Articles » PMID: 36734885

Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2023 Feb 3
PMID 36734885
Authors
Jing Zou
Chaitanya Kurhade
Sohil Patel
Nicholas Kitchin
Kristin Tompkins
Mark Cutler
David Cooper
Qi Yang
Hui Cai
Alexander Muik
Ying Zhang
Dung-Yang Lee
Ugur Sahin
Annaliesa S Anderson
William C Gruber
Xuping Xie
Kena A Swanson
Pei-Yong Shi
Affiliations
Soon will be listed here.
Citing Articles

Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants.

Launay O, Gupta R, Machabert T, Konate E, Rousseau A, Vigne C Commun Med (Lond). 2025; 5(1):21.

PMID: 39827332 PMC: 11742922. DOI: 10.1038/s43856-024-00675-9.

Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.

Yang J, Hong W, Shi H, He C, Lei H, Zhou Y Nat Commun. 2024; 15(1):10778.

PMID: 39738039 PMC: 11686202. DOI: 10.1038/s41467-024-55087-z.

Emerging mutation in SARS-CoV-2 facilitates escape from NK cell recognition and associates with enhanced viral fitness.

Bilev E, Wild N, Momayyezi P, Sala B, Sun R, Sandalova T PLoS Pathog. 2024; 20(12):e1012755.

PMID: 39652590 PMC: 11658698. DOI: 10.1371/journal.ppat.1012755.

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.

Orbo H, de Matos Kasahara T, Wolf A, Bjorlykke K, Sexton J, Jyssum I Lancet Reg Health Eur. 2024; 48:101121.

PMID: 39624496 PMC: 11609505. DOI: 10.1016/j.lanepe.2024.101121.

Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States.

Kopel H, Nguyen V, Bogdanov A, Winer I, Boileau C, Ducruet T Vaccines (Basel). 2024; 12(10).

PMID: 39460274 PMC: 11511346. DOI: 10.3390/vaccines12101107.

References
1.
Davis-Gardner M, Lai L, Wali B, Samaha H, Solis D, Lee M . Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; 388(2):183-185. PMC: 9812288. DOI: 10.1056/NEJMc2214293. View
2.
Cele S, Jackson L, Khoury D, Khan K, Moyo-Gwete T, Tegally H . Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022; 602(7898):654-656. PMC: 8866126. DOI: 10.1038/s41586-021-04387-1. View
3.
Liu Z, VanBlargan L, Bloyet L, Rothlauf P, Chen R, Stumpf S . Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021; 29(3):477-488.e4. PMC: 7839837. DOI: 10.1016/j.chom.2021.01.014. View
4.
Muruato A, Fontes-Garfias C, Ren P, Garcia-Blanco M, Menachery V, Xie X . A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020; 11(1):4059. PMC: 7426916. DOI: 10.1038/s41467-020-17892-0. View
5.
Kurhade C, Zou J, Xia H, Liu M, Yang Q, Cutler M . Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerg Microbes Infect. 2022; 11(1):1828-1832. PMC: 9331225. DOI: 10.1080/22221751.2022.2099305. View